Financial Comparison of Bristol-Myers Squibb and Orion OYJ
1 report, 1 independent
Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A report compared Bristol-Myers Squibb to Orion OYJ, two large-cap healthcare companies. The comparison found that Bristol-Myers Squibb has higher revenue and earnings per share than Orion OYJ, while trading at a lower price-to-earnings ratio. Bristol-Myers Squibb also has a longer track record of dividend growth, having raised its dividend for 17 consecutive years.
From themarketsdaily.com
Why it matters
The comparison of financial metrics, including dividend yield and valuation, may influence investor decisions regarding the companies' market positioning and investment appeal.
From themarketsdaily.com
Who's involved
- Bristol-Myers SquibbAmerican pharmaceutical company subject to financial analysis
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.
- Manufacturers Life Insurance Company reduced its share position in Bristol-Myers Squibb.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- MarketBeat reported consensus analyst targets and compared financial health for Bristol-Myers Squibb and Shionogi & Co., Ltd.